In the field of biotechnology and cancer therapies and research, the contributions made by Clay Siegall are immense. He co-founded Seattle Genetics in 1998 and is currently the Chairman, President, and CEO of the company. Under his leadership, Seattle Genetics, which deals mostly in developing antibody-conjugates, received approval from FDA in 2011 for its first-ever ADC product named ADCETRIS.
With the help of a partnership with another pharmaceutical giant, Takeda Pharmaceutical Company, Clay Siegall has been able to promote ADCETRIS as a global brand with active distribution channels in over 60 countries. And, with the success of ADCETRIS, the company is also researching and developing a line of other ADC products for the comprehensive and effective treatment of cancer.
With that said, Clay Siegall has not only focused on the science part of the company but has equally focused on the business front. Through his efforts and endeavors, the company has been able to raise funds, both public and private, more than $670 million. This has given the Seattle Genetics that much-needed equity boost it needed to advance rapidly in the segments it has been lagging behind and has overall given it a fair competitive advantage it needed. Along with heading Seattle Genetics, Siegall is also one of the directors at Biomedical Association, Washington Biotechnology, and Alder Bio Pharmaceuticals.
The scientific acumen of Siegall can be seen in his achievements so far in his career, which includes holding 15 patents and authoring over 70 publications in noted international science and medical journals. He holds a degree of B.S. in Zoology from the University of Maryland and completed his Ph.D. in Genetics from George Washington University. The dedication of Clay Siegall and his company Seattle Genetics over the period of 19 years has helped the field of cancer research and therapies immensely, as it developed many ADCs that are currently in use worldwide. The company to makes it global footprint stronger has collaborated at various levels and scales with other biotechnology companies worldwide.
One of the collaborations, valued at over $860 million includes the one with Genetech for SGN-40. Clay Siegall is one of the most dynamic personalities in the biotechnology industry today, blessed with scientific knowledge and business insight, a combination that is sure to not only help his company grow in the years to come but also contribute towards the advancement of cancer research and therapies.